Revisiting conclusions on the empiric segmentation of high-risk patients

Am J Manag Care. 2022 Jun;28(6):251-252. doi: 10.37765/ajmc.2022.89153.

Authors

Veronique Michaud, Pamela Dow, Jacques Turgeon¹

Affiliation

¹ Precision Pharmacotherapy Research and Development Institute, Tabula Rasa HealthCare, 13485 Veterans Way, Ste 410, Orlando, FL 32827. Email: jturgeon@trhc.com.

PMID: 35738220
DOI: 10.37765/ajmc.2022.89153

Abstract

The authors provide feedback on generalizations made regarding interventions for high-risk populations in previous research.